MedTrace Logo

A Study in Patients With Trichotillomania

NCT03797521 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2021-10-28

No results posted yet for this study

Summary

The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.

Conditions

  • Trichotillomania

Interventions

DRUG

SXC-2023

SXC-2023 oral capsules

DRUG

Placebo

Matching Placebo oral capsules

Sponsors & Collaborators

  • Promentis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Dean Brostowin · Promentis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-19
Primary Completion
2019-12-02
Completion
2019-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03797521 on ClinicalTrials.gov